Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew et al. · Blood · 2001 · 1.5K citations · Full text

Acute Myeloid Leukemia

Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +10

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

Susanne Schnittger, Claudia Schoch, Martin Dugas et al. · Blood · 2002 · 962 citations · Full text

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 856 citations · Full text